Related Experiment Video
Updated: Jun 14, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Alefacept treatment for chronic plaque psoriasis
1Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, US.
Skin Therapy Letter
|April 3, 2010
Summary
Biologic agents offer new chronic psoriasis treatments. Alefacept, the first biologic, shows efficacy, safety, and cost-effectiveness for plaque psoriasis based on clinical trial data.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Biologic agents represent a novel therapeutic class for chronic psoriasis.
- They offer alternatives to conventional topical and systemic treatments.
- Psoriasis is a chronic inflammatory skin condition requiring effective long-term management.
Purpose of the Study:
- To review clinical trial data on alefacept for chronic plaque psoriasis.
- To evaluate the efficacy, safety, and cost-effectiveness of alefacept.
- To provide insights into alefacept's role in psoriasis treatment.
Main Methods:
- Review of clinical trial data.
- Analysis of efficacy, safety, and cost-effectiveness metrics.
- Synthesis of evidence regarding alefacept's therapeutic profile.
Main Results:
- Alefacept, approved in 2003, is the first biologic agent for chronic plaque psoriasis.
- Clinical trials provide new insights into its therapeutic value.
- Data covers efficacy, safety, and economic considerations.
Conclusions:
- Alefacept offers a new treatment option for chronic psoriasis.
- Further insights into its clinical utility are discussed.
- The review highlights its place among psoriasis therapies.
Related Concept Videos
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...